Blackstone group invests up to $2 billion in alnylam, a big bet on the cambridge biotech
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
The private equity firm Blackstone Group is investing up to $2 billion in Alnylam Pharmaceuticals, a big bet on the Cambridge biotech’s approach to developing drugs for genetic diseases and
disorders that need better treatments. The deal, which was announced Monday, is anchored by Blackstone’s purchase of half the royalties owed to Alnylam on global sales of inclisiran, an
experimental RNA interference drug for the treatment of high cholesterol. Inclisiran is a twice-a-year injected RNAi therapeutic that reduced bad cholesterol in a late-stage clinical trial.
If approved, the medicine is expected to help reduce a major risk factor for cardiovascular disease, the leading global cause of death, according to Alnylam. STAT+ Exclusive Story Already
have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS DAILY COVERAGE AND ANALYSIS OF THE BIOTECH SECTOR — BY SUBSCRIBING TO STAT+. Already have an
account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe